Claims for Patent: 10,155,050

Summary for Patent: 10,155,050

Title:	Cross-linked star-shaped self-assembled polypeptides and its use as carriers in biomedical applications
Abstract:	The invention relates to 3-arms star-shaped polypeptides derivatives which are able to self-assemble to form bioresponsive nanometric globular structures with controllable size and shape. These multivalent constructs also present the ability of disassemble under specific physiological conditions and of linking to at least one active agent so that they can be used as carries in biomedical applications.
Inventor(s):	Vicent Docon; Maria Jes s (Valencia, ES), Duro Castano; Aroa (Valencia, ES), Nebot Carda; Vicent Josep (Valencia, EP)
Assignee:	CENTRO DE INVESTIGACION PRINCIPE FELIPE (Valencia, ES)
Application Number:	15/751,137
Patent Claims:	1. A compound of formula (I) below, comprising homopolypeptides or random or block co-polypeptides: ##STR00072## or its salts, solvates or isomers, wherein: m, m', m'', n, n', n'', o, o' and o'' are integers independently selected from 0 to 500, wherein at least one of them is .gtoreq.1; R.sub.6 to R.sub.8, R.sub.6' to R.sub.8' and R.sub.6'' to R.sub.8'' are independently selected from H and methyl; I.sub.1 to I.sub.3 are independently selected from the group consisting of H; halogen; Deuterium; and (C.sub.1-C.sub.20)-alkyl; R.sub.2 to R.sub.4, R.sub.2' to R.sub.4' and R.sub.2'' to R.sub.4'' are independently selected from the group consisting of: ##STR00073## X.sub.1 and X.sub.2 are independently selected from the group consisting of H; N; NH.sub.2; and Z; X.sub.3 and X.sub.4 are independently selected from the group consisting of H; and Z; y and y' are integers between 0 and 3; and y+y'=2 or 3; y'' and y''' are integers between 0 and 2; and y+y'=1 or 2 Z is selected from the group consisting of H; metallic counterion; inorganic counterion; and an amino acid protecting group; R.sub.1, R.sub.1' and R.sub.1'' are radicals independently selected from the group consisting of: ##STR00074## A.sub.1, A.sub.2, A.sub.3 and A.sub.4 are radicals independently selected from the group as defined for R.sub.2 to R.sub.4, R.sub.2' to R.sub.4', and R.sub.2'' to R.sub.4''; L.sub.1 is a radical independently selected from the group consisting of a (C.sub.1-C.sub.500)-alkyl, wherein one or more H is optionally substituted by: (1) (C.sub.3-C.sub.30)-cycloalkyl, (2) a C-radical derived from a ring system with 1-6 rings, each ring being independently saturated, partially unsaturated or aromatic, the rings being isolated or fused and having 3-20 members each member independently selected from the group consisting of C, CH, CH.sub.2, CO, N and NH, (3) OH, (4) NR.sub.aR.sub.b, (5) ONR.sub.cR.sub.d, (6) CN, (7) halide, (8) SH.sub.2, (9) SR.sub.eR.sub.f, (10) N(H)NH.sub.2, (11) R.sub.gCOR.sub.h, (12) COOR.sub.i, (13) CON(R.sub.j)(R.sub.k), (14) R.sub.lN(R.sub.m)CON(R.sub.n).sub.2, (15) (C.sub.1-C.sub.30)-alkene, (16) (C.sub.1-C.sub.30)-alkyne, (17) N.sub.3, (18) R.sub.oCH(OR.sub.p)(OR.sub.q), (19) R.sub.rCH(SR.sub.s)(SR.sub.t), (20) R.sub.nBoron(OR.sub.v)(OR.sub.w), (21) COR.sub.x; and wherein one of more C are independently replaced by (C.sub.3-C.sub.30)-cycloalkyl, aryl, aryl-(C.sub.1-C.sub.30)-alkyl, NR.sub.yR.sub.z, CO, O, S, Boron, halide, P and (O--CH.sub.2--CH.sub.2).sub.B; B is an integer between 1 and 500; R.sub.a, R.sub.b, R.sub.c, R.sub.d, R.sub.e, R.sub.f, R.sub.h, R.sub.i, R.sub.j, R.sub.k, R.sub.m, R.sub.n, R.sub.p, R.sub.q, R.sub.s, R.sub.t, R.sub.v, R.sub.w, R.sub.x, R.sub.y and R.sub.z are radicals independently selected from the group consisting of H; (C.sub.1-C.sub.30)-alkyl; (C.sub.1-C.sub.30)-alkylphenyl; phenyl (C.sub.1-C.sub.30)-alkyl; and (C.sub.3-C.sub.8)-cycloalkyl, wherein one or more carbons are optionally substituted by an heteroatom selected from the group consisting of O; S; F; N; NH; P; and CO; R.sub.g, R.sub.l, R.sub.o, R.sub.r and R.sub.u are radicals independently selected from the group consisting of (C.sub.1-C.sub.30)-alkyl; (C.sub.1-C.sub.30)-alkylphenyl; phenyl; (C.sub.1-C.sub.30)-alkyl; and (C.sub.3-C.sub.8)-cycloalkyl, wherein one or more carbons are optionally substituted by an heteroatom selected from the group consisting of O; S; F; N; NH; P; and CO; R.sub.5, R.sub.5' and R.sub.5'' are radicals independently selected from the group consisting of H; and (C.sub.1-C.sub.500)-alkyl, optionally substituted by: (1) (C.sub.3-C.sub.30)-cycloalkyl, (2) a C-radical derived from a ring system with 1-6 rings, each ring being independently saturated, partially unsaturated or aromatic, the rings being isolated or fused and having 3-20 members each member independently selected from the group consisting of C, CH, CH.sub.2, CO, N and NH, (3) OH, (4) NR.sub.aR.sub.b, (5) ONR.sub.cR.sub.d, (6) CN, (7) halide, (8) SH.sub.2, (9) SR.sub.eR.sub.f, (10) N(H)NH.sub.2, (11) R.sub.gCOR.sub.h, (12) COOR.sub.i, (13) CON(R.sub.j)(R.sub.k), (14) R.sub.lN(R.sub.m)CON(R.sub.n).sub.2, (15) (C.sub.1-C.sub.30)-alkene, (16) (C.sub.1-C.sub.30)-alkyne, (17) N.sub.3, (18) R.sub.oCH(OR.sub.p)(OR.sub.q), (19) R.sub.rCH(SR.sub.s)(SR.sub.t), (20) R.sub.uBoron(OR.sub.v)(OR.sub.w), (21) COR.sub.x; and wherein one of more C are independently replaced by (C.sub.3-C.sub.30)-cycloalkyl, aryl, aryl-(C.sub.1-C.sub.30)-alkyl, NR.sub.yR.sub.z, CO, O, S, Boron, halide, P and (O--CH.sub.2--CH.sub.2).sub.B; B is an integer between 1 and 500; R.sub.a, R.sub.b, R.sub.c, R.sub.d, R.sub.e, R.sub.f, R.sub.h, R.sub.i, R.sub.j, R.sub.k, R.sub.m, R.sub.n, R.sub.p, R.sub.q, R.sub.s, R.sub.t, R.sub.v, R.sub.w, R.sub.x, R.sub.y and R.sub.z are radicals independently selected from the group consisting of H; (C.sub.1-C.sub.30)-alkyl; (C.sub.1-C.sub.30)-alkylphenyl; phenyl (C.sub.1-C.sub.30)-alkyl; and (C.sub.3-C.sub.8)-cycloalkyl, wherein one or more carbons are optionally substituted by an heteroatom selected from the group consisting of O; S; F; N; NH; P; and CO; R.sub.g, R.sub.l, R.sub.o, R.sub.r and R.sub.u are radicals independently selected from the group consisting of (C.sub.1-C.sub.30)-alkyl; (C.sub.1-C.sub.30)-alkylphenyl; phenyl; (C.sub.1-C.sub.30)-alkyl; and (C.sub.3-C.sub.8)-cycloalkyl, wherein one or more carbons are optionally substituted by an heteroatom selected from the group consisting of O; S; F; N; NH; P; and CO. 2. The compound according to claim 1, wherein: I.sub.1, I.sub.2 and I.sub.3, are radicals independently selected from the group consisting of H; Deuterium; and F; R.sub.5, R.sub.5' and R.sub.5''' are identical between them and selected from the group consisting of H; CO--(C.sub.1-C.sub.20)-alkyl; CONH--(C.sub.1-C.sub.20)-alkyl; and pyroglutamate. 3. The compound according to claim 1, wherein: R.sub.2.dbd.R.sub.2'.dbd.R.sub.2'', R.sub.3.dbd.R.sub.3'.dbd.R.sub.3'', and R.sub.4.dbd.R.sub.4'.dbd.R.sub.4'', and each of them is independently selected from the group consisting of: ##STR00075## X.sub.1 and X.sub.2 are independently selected from the group consisting of H; N; --NH.sub.2; and Z; y and y' are integers between 0 and 3; and y+y'=2 or 3; R.sub.1.dbd.R.sub.1'.dbd.R.sub.1'' and R.sub.1 is selected from: ##STR00076## A.sub.1, A.sub.2, A.sub.3 and A.sub.4 denote the side residues of hydrophobic amino acids and they are selected from the group consisting of: ##STR00077## and combinations thereof. 4. A compound of formula (II): ##STR00078## or its salts, solvates or isomers wherein: R.sub.1 to R.sub.8, I.sub.1 to I.sub.3, n, and o, are defined as in claim 1; m is an integer between 2-500; x is a number from 0.01*m to 0.5*m; R.sub.2''' is a radical selected from the group consisting of: ##STR00079## X.sub.1 is H; y is 0 or 1; CL is a radical selected from the group consisting of a (C.sub.1-C.sub.500)-alkyl, wherein one or more H is optionally substituted by: (1) (C.sub.3-C.sub.30)-cycloalkyl, (2) a C-radical derived from a ring system with 1-6 rings, each ring being independently saturated, partially unsaturated or aromatic, the rings being isolated or fused and having 3-20 members each member independently selected from the group consisting of C, CH, CH.sub.2, CO, N and NH, (3) OH, (4) NR.sub.aR.sub.b, (5) ONR.sub.cR.sub.d, (6) CN, (7) halide, (8) SH.sub.2, (9) SR.sub.eR.sub.f, (10) N(H)NH.sub.2, (11) R.sub.gCOR.sub.h, (12) COOR.sub.i, (13) CON(R.sub.j)(R.sub.k), (14) R.sub.lN(R.sub.m)CON(R.sub.n).sub.2, (15) (C.sub.1-C.sub.30)-alkene, (16) (C.sub.1-C.sub.30)-alkyne, (17) N.sub.3, (18) R.sub.oCH(OR.sub.p)(OR.sub.q), (19) R.sub.rCH(SR.sub.s)(SR.sub.t), (20) R.sub.uBoron(OR.sub.v)(OR.sub.w), (21) COR.sub.x; and wherein one of more C are independently replaced by (C.sub.3-C.sub.30)-cycloalkyl, aryl, aryl-(C.sub.1-C.sub.30)-alkyl, NR.sub.yR.sub.z, CO, O, S, Boron, halide, P and (O--CH.sub.2--CH.sub.2).sub.B; B is an integer between 1 and 500; R.sub.a, R.sub.b, R.sub.c, R.sub.d, R.sub.e, R.sub.f, R.sub.h, R.sub.i, R.sub.j, R.sub.k, R.sub.m, R.sub.n, R.sub.p, R.sub.q, R.sub.s, R.sub.t, R.sub.v, R.sub.w, R.sub.x, R.sub.y and R.sub.z are radicals independently selected from the group consisting of H; (C.sub.1-C.sub.30)-alkyl; (C.sub.1-C.sub.30)-alkylphenyl; phenyl (C.sub.1-C.sub.30)-alkyl; and (C.sub.3-C.sub.8)-cycloalkyl, wherein one or more carbons are optionally substituted by an heteroatom selected from the group consisting of O; S; F; N; NH; P; and CO; R.sub.g, R.sub.l, R.sub.o, R.sub.r and R.sub.u are radicals independently selected from the group consisting of (C.sub.1-C.sub.30)-alkyl; (C.sub.1-C.sub.30)-alkylphenyl; phenyl; (C.sub.1-C.sub.30)-alkyl; and (C.sub.3-C.sub.8)-cycloalkyl, wherein one or more carbons are optionally substituted by an heteroatom selected from the group consisting of O; S; F; N; NH; P; and CO. 5. The compound according to claim 4, wherein: I.sub.1, I.sub.2 and I.sub.3, are radicals independently selected from the group consisting of H; Deuterium; and F; R.sub.5 is selected from the group consisting of H; CO--(C.sub.1-C.sub.20)-alkyl; CONH--(C.sub.1-C.sub.20)-alkyl; and pyroglutamate. 6. The compound according to claim 4, wherein: each R.sub.2, R.sub.3, and R.sub.4 is independently selected from the group consisting of: ##STR00080## X.sub.1 and X.sub.2 are defined as in claim 1; y and y' are defined as in claim 1; R.sub.1 is selected from the following groups: ##STR00081## A.sub.1, A.sub.2, A.sub.3 and A.sub.4 denote the side residues of hydrophobic amino acids and they are selected from the following groups or combinations thereof: ##STR00082## L.sub.1 is as defined in claim 1. 7. The compound according to claim 4, wherein: R.sub.2''' is selected from the group consisting of: ##STR00083## X.sub.1 is H; y is 0 or 1; CL is selected from the group consisting of: ##STR00084## R.sub.9 and R.sub.11 to R.sub.17 are independently selected from the group consisting of: ##STR00085## p and s are integers independently selected from 0 to 500; R.sub.10 is selected from H and (C.sub.1-C.sub.4)-alkyl. 8. A cross-linked self-assembled star polymer comprising a recurring unit of formula (III): ##STR00086## or its salts, solvates or isomers wherein: R.sub.1 to R.sub.8, I.sub.1 to I.sub.3, m, n and o are defined as in claim 1; x is a, number from 0.01*m to 0.5*m; R.sub.2''' is selected from the group consisting of: ##STR00087## X.sub.1 and y are defined as in claim 4; CL.sub.1 is defined as CL in claim 4. 9. The cross-linked self-assembled star polymer according to claim 8, wherein: I.sub.1, I.sub.2, and I.sub.3, are radicals independently selected from the group consisting of H; Deuterium; and F; R.sub.5 is selected from the group consisting of H; CO--(C.sub.1-C.sub.20)-alkyl; CON(H)--(C.sub.1-C.sub.20)-alkyl; and pyroglutamate. 10. The cross-linked self-assembled star polymer according to claim 9, wherein: each R.sub.2, R.sub.3, and R.sub.4 is independently selected from the group consisting of: ##STR00088## X.sub.1 and X.sub.2 are defined as in claim 1; y and y' are defined as in claim 1; R.sub.1 is selected from the following groups: ##STR00089## A.sub.1, A.sub.2, A.sub.3 and A.sub.4 denote the side residues of hydrophobic amino acids and they are selected from the following groups or combinations thereof: ##STR00090## L.sub.1 is as defined in claim 1. 11. The cross-linked self-assembled star polymer according to claim 8, wherein: R.sub.2''' is selected from the group consisting of: ##STR00091## X.sub.1 and y are defined as in claim 4; CL.sub.1 is selected from the group consisting of: ##STR00092## R.sub.9 and R.sub.11 to R.sub.17 are selected from the group consisting of: ##STR00093## p and s are integers independently selected from 0 to 500; R.sub.10 is selected from H and (C.sub.1-C.sub.4)-alkyl. 12. A conjugate comprising the compound of formula (I) as defined in claim 1, the compound of formula (II) as defined in claim 4, or the cross-linked self-assembled star polymer of formula (III) as defined in claim 8, and at least an active agent which is linked to the compound or the self-assembled star polymer. 13. The conjugate according to claim 12 wherein the at least active agent is selected from the group consisting of an active ingredient and an imaging agent, or combinations thereof. 14. The conjugate according to claim 13, wherein the at least active ingredient is selected from the group consisting of anticancer agent, antimetastatic agent, anti-inflammatory agent, antioxidant, antiapoptotic, proapoptotic, neuroprotective agent, immunostimulant agent, antioxidants, agent capable to trigger tissue repair and/or regeneration, anti-amyloidotic agent, and plaque/protein aggregates disrupting agents. 15. The conjugate according to claim 14, wherein the at least active ingredient is selected from the group consisting of: vincristine, vinblastine, amiloride, chloroquine, blafiomycyn, fasudil, bisphosphonate, primaquine, meclofenamate, tonabersat, disulfiram, cyclophosphamide, paclitaxel, dendrotoxin, doxorubicine, methotrexate, epirubicine, dinaciclib, buparlisib, palbociclib, veliparib, megestrol, examestane, goserelin, tamoxifen, fulvestrant, trastuzumab, lapatinib, pertuzumab, selegiline, rasagiline, ladostigilM30, demethoxycurcumin, curcumin, and bisdemethoxycurcumin. 16. The conjugate according to claim 12, wherein the conjugate comprises an amount of the at least an active agent in the range between 1 to 70% w/w based on the mass ratio of the at least active agent to the conjugate. 17. A pharmaceutical, diagnostic or theranostic composition comprising at least one conjugate as defined in claim 12 together with one or more appropriate pharmaceutical or diagnostically acceptable excipients. 18. A method for treatment of a neurodegenerative disorder, neurological disease, cancer, infectious disease, disorder related to aging, neuro-inflammation, demyelinating disorder, multiple sclerosis, ischemic disorder, ischemia-reperfusion induced damage, amyloydotic disease, cardiomyopathy, spinal cord injury, immune disorder, inflammatory disorders, rare disease, wound healing and lysosomal storage disease comprising administering the conjugate according to claim 12. 19. A carrier comprising a compound of formula (I) as defined in claim 1, the compound of formula (II) as defined in claim 4, or the cross-linked self-assembled star polymer of formula (III) as defined in claim 8. 20. A process for the synthesis of the compound of formula (I) as defined in claim 1, the process comprising: (1) reacting an amine or TFA/BF4 salt initiator of formula (IV) below ##STR00094## wherein I.sub.1 to I.sub.3, R.sub.1, R.sub.1' and R.sub.1'' are as defined in any of the claims 1-3, with an appropriate N-carboxyanhydride (NCA); alternatively, reacting the amine or tetrafluoroborate or trifluoroacetate ammonium salt form of initiator of step (1) with the appropriate N-carboxyanhydrides in a sequential manner to obtain a block co-polymer; alternatively, reacting the amine or tetrafluoroborate or trifluoroacetate ammonium salt form of initiator of step (1) with an appropriate NCA in a statistical manner to obtain random co-polymers; (2) optionally, reacting the amine group at the N-terminal position with an amine reactive group to introduce R.sub.5, R.sub.5' and/or R.sub.5''; (3) optionally, orthogonally removing amino acid side chains; (4) purifying the product obtained in step (1), (2) or (3), optionally by fractionation, precipitation, ultrafiltration, dialysis, size exclusion chromatography or tangential flow filtration. 21. A process as defined in claim 20, for the synthesis of the compound of formula (II) as defined in claim 4, the process further comprising: (5) introducing the CL groups at reactive amino acid side chain, at the appropriate molar ratio; (6) purifying the product obtained in step (5) optionally by fractionation, precipitation, ultrafiltration, dialysis, size exclusion chromatography or tangential flow filtration. 22. A process as defined in claim 21, for the synthesis of the cross-linked self-assembled star polymer of formula (III) as defined in claim 8, the process further comprising: (7) reacting the CL groups of the self-assembled compounds of formula (II) forming nanometric assemblies, to covalently cross-link the self-assembled star polymers; (8) purifying the product obtained in step (7) optionally by fractionation, precipitation, ultrafiltration, dialysis, size exclusion chromatography or tangential flow filtration.

Details for Patent 10,155,050

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2035-08-07
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2035-08-07
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2035-08-07
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2035-08-07